Articular Cartilage DefectsExtensionNCT01251588
Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee
An observational study of Articular Cartilage Defects, run by Vericel Corporation at 14 sites in 7 countries.
Trial summary
To examine the 5-year efficacy and safety of MACI implant, compared with arthroscopic microfracture, in participants who received study treatment in the SUMMIT study for treatment of symptomatic articular cartilage defects of the knee. Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Articular Cartilage Defects
- What is being tested?
- autologous cultured chondrocytes on porcine collagen membrane and Microfracture
- Type of treatment
- Surgery or procedure
- How many people
- 128 participants
- Where
- 14 sitesin 7 countries
- Study dates
- Dec 2010to Mar 2015
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Study population: Randomized and received study treatment (MACI or microfracture) in the SUMMIT study.
Randomized and received study treatment (MACI or microfracture) in the SUMMIT study.
Trial locations and contacts
14 sites in 7 countries.
14 sites in 7 countries
France3 sites
Polyclinique Saint-Roch
Montpellier, 34967
Clinique Maussins-Nollet
Paris, 75019
Hôpital d'instruction des Armées Robert Picqué
Villenave-d'Ornon, 33882
Netherlands3 sites
Academisch Ziekenhuis Maastricht
Maastricht, 6202 AZ
St. Elisabeth Ziekenhuis
Tilburg, 5022 GC
University Medical Centre of Utrecht, Department of Orthopaedics
Utrecht, 3508 GA
Poland3 sites
Orthopaedic & Traumatology of Motor Organs, Independent Public Clinic Hospital
Bydgoszcz, 85-094
Regional Centre of Knee Surgery & Arthroscopy, Regional Hospital of Traumatologic Surgery
Piekary Śląskie, 41-940
Lekmed Medical Center
Warszewo, 01-480
Czechia2 sites
Urazova nemocnice v Brne
Brno, 662 50
University Hospital Na Bulovce- Department of Orthopaedic Surgery Postgraduate Medical Institute
Prague, 180 81
United Kingdom1 site
University of Oxford, Nuffield Dept. of Orthopaedic Surgery
Oxford, OX3 7LD
About this study
Official title: An Extension Protocol for Participants of Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle Including the Trochlea
To examine the 5-year efficacy and safety of MACI implant, compared with arthroscopic microfracture, in participants who received study treatment in the SUMMIT study for treatment of symptomatic articular cartilage defects of the knee.
Read the detailed description
This study was an open-label, multicenter extension to the SUMMIT study designed to examine the 5-year efficacy and safety of MACI compared to arthroscopic microfracture in the treatment of articular cartilage defects of the knee in participants who received study treatment in the SUMMIT study. Follow-up to 2 years post-study treatment was completed as part of the SUMMIT study. Follow-up from 3 to 5 years post-study treatment in SUMMIT was completed in this extension study.
All 144 participants who received study treatment in the SUMMIT study were eligible for enrollment into this extension study. Participants had until the end of the visit window for the last visit of this extension study (ie, Week 260 + 6 weeks) to consent to enter this extension study.
Efficacy and safety assessments were performed at scheduled visits 3, 4, and 5 years following treatment in SUMMIT (ie, at Weeks 156, 208, and 260 postarthrotomy for patients treated with MACI implant or at Weeks 156, 208, and 260 postarthroscopy for patients treated with microfracture).
- Conditions
- Articular Cartilage Defects
- Being tested
- autologous cultured chondrocytes on porcine collagen membrane, Microfracture
- Keywords
- Cartilage legions, Symptomatic focal cartilage defects, Microfracture, MACI, Autologous chondrocyte
- Medical subject headings
- Fractures, Stress
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
autologous cultured chondrocytes on porcine collagen membraneBiological
Also called MACI, matrix applied characterized autologous cultured chondrocytes
Implantation received in the previous MACI00206 study
MicrofractureProcedure or surgery
Arthroscopic Microfracture treatment received in the previous MACI00206 study
| Study group | Role | What they receive |
|---|---|---|
| MACI | autologous cultured chondrocytes on porcine collagen membrane implant received in previous MACI00206 study Receives: Biological: autologous cultured chondrocytes on porcine collagen membrane | |
| Microfracture | Microfracture treatment received in previous MACI00206 study Receives: Procedure: Microfracture |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From MACI00206 Baseline for the Participant's Knee Injury and Osteoarthritis Outcome (KOOS) Pain and Function (Sports and Recreational Activities) Scores.
The KOOS is a validated knee-specific instrument developed to assess the patients' opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). A 5-point Likert scale was used to record the response to each item ranging from 0 (no problems) to 4 (extreme problems). Within each subscale, items were added up and normalized to a value between 0 (extreme problems) and 100 (no problems). Subscales are not combined to calculate a total score.
Measured: MACI00206 Baseline to Week 156
Secondary outcomes (13)
Change From MACI00206 Baseline for the Participant's KOOS Pain and Function (Sports and Recreational Activities) Scores
The KOOS is a validated knee-specific instrument developed to assess the patients' opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). A 5-point Likert scale was used to record the response to each item ranging from 0 (no problems) to 4 (extreme problems). Within each subscale, items were added up and normalized to a value between 0 (extreme problems) and 100 (no problems). Subscales are not combined to calculate a total score.
Measured: MACI00206 Baseline and Week 260
Magnetic Resonance Imaging (MRI) Assessments of Degree of Defect Fill
MRI was assessed by the independent blinded evaluators by means of consensus. The number of participants with a degree of defect fill of >50% is reported.
Measured: Week 260
Proportion of Patients Who Achieve at Least a 10-point Improvement From MACI00206 Baseline in KOOS Pain and Function (Sports and Recreational Activities) Scores
A responder is defined as a participant with at least a 10-point improvement in both the KOOS Pain and Function (Sports and Recreational activities) scores from MACI00206 Baseline scores.
Measured: Up to week 260
The Proportion of Patients in Each Treatment Group Assessed as Treatment Failures
Patients were considered as a treatment failure if all of the following 5 criteria were met:
- Patient's global assessment of their knee joint compared to Baseline was the same or worse
- Physician's global assessment of the patient's knee joint compared to Baseline was the same, worse, or significantly worse.
- Percent improvement from Baseline in KOOS Pain score was less than 10%.
- Physician diagnostic evaluation of failure excluded etiologies (eg, meniscal tear) other than failed treatment of the index lesion.
- The physician decided that surgical re-treatment of the index lesion(s) was required that involved either extensive debridement for lesion expansion, violation of the subchondral bone, or ACI.
Measured: Years 2 through 5 post treatment (MACI or microfracture)
Average Time to Treatment Failure
ANALYSIS NOT DONE: The planned analyses concerning time to treatment failure were not conducted due to the small number of per protocol treatment failure cases. The number of per protocol treatment failures in each treatment group are reported here.
Patients were considered as a treatment failure if all of the following 5 criteria were met:
- Patient's global assessment of their knee joint compared to Baseline was the same or worse
- Physician's global assessment of the patient's knee joint compared to Baseline was the same, worse, or significantly worse.
- Percent improvement from Baseline in KOOS Pain score was less than 10%.
- Physician diagnostic evaluation of failure excluded etiologies (eg, meniscal tear) other than failed treatment of the index lesion.
- The physician decided that surgical re-treatment of the index lesion(s) was required that involved either extensive debridement for lesion expansion, violation of the subchondral bone, or ACI.
Measured: Up to 260 weeks
Change From MACI00206 Baseline in the Remaining 3 Subscales (Activities of Daily Living, Quality of Life, and Other Symptoms) of KOOS
The KOOS is a validated knee-specific instrument developed to assess the patients' opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). A 5-point Likert scale was used to record the response to each item ranging from 0 (no problems) to 4 (extreme problems). Within each subscale, items were added up and normalized to a value between 0 (extreme problems) and 100 (no problems). Subscales are not combined to calculate a total score.
Measured: MACI00206 Baseline and Week 260
Change From MACI00206 Baseline in the Patient's Evaluation of Overall Knee Condition Using the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form
The IKDC Subjective Knee Evaluation Form is a validated knee-specific measure of symptoms, function, and sports activity that is appropriate for patients with a wide variety of knee problems. The form consists of 18 items covering the domains of symptoms, functioning during activities of daily living and sports, and current function of the knee.
The IKDC Subjective Knee Evaluation Form is scored by summing the scores for the individual items and then transforming the score to a scale that ranges from 0 to 100. The transformed score is interpreted as a measure of function such that higher scores represent higher levels of function and lower levels of symptoms. A score of 100 is interpreted to mean no limitation with activities of daily living or sports activities and the absence of symptoms.
Measured: MACI00206 Baseline and Week 260
Change From MACI00206 Baseline in the Patient's Evaluation of Overall Knee Condition Using the Modified Cincinnati Knee Rating System
The Modified Cincinnati Knee Rating System is a self-assessment of the intensity of sports participation, functional limitations, and the ability to participate in different types of sports. The Modified Cincinnati Knee Rating System overall knee condition score ranges from 1 (poor) to 10 (excellent).
Measured: MACI00206 Baseline and Week 260
Change From MACI00206 Baseline in the 12-Item Short-Form Health Survey (SF-12) Physical and Mental Component Scores
The SF-12 is a subset of the 36-Item Short-Form Health Survey (SF-36) and includes 8 subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) that are used to calculate the physical (PCS) and mental (MCS) summary component scores.
MCS and PCS are summarized as Z-scores using standard SF-12 scoring and a US population means. The Z-score indicates how many standard deviations a score is from the population mean. Higher values reflect better health. Changes from Baseline are reported.
Measured: MACI00206 Baseline and Week 260
Change From MACI00206 Baseline in the European Quality of Life 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) Score
The EQ-5D is a standardized instrument for use as a measure of health outcome (see the EuroQOL Website for details: www.euroqol.org). Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status. The EQ Visual Analogue Scale (VAS) was used to record the respondents' self-rated health status on a vertical graduated (0-100) VAS where 0 is 'the worst health you can imagine' and 100 is 'the best health you can imagine'.
Measured: MACI00206 Baseline and Week 260
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs)
Measured: Years 2 through 5 post treatment (MACI or microfracture)
Number of Participants Reporting Serious Adverse Events (SAEs)
Measured: Years 2 through 5 post treatment (MACI or microfracture)
Number of Participants Having Subsequent Surgical Procedures (SSPs) in Target Knee
Measured: Years 2 through 5 post treatment (MACI or microfracture)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2010 (estimated)
- Study startDec 2010
- Primary completionMar 2015
- Study completionMar 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Articular Cartilage DefectsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 128 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vericel Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Monitor, Study director, Genzyme, a Sanofi Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01251588
- Sponsor's protocol ID
- MACI00809
- Other IDs
- 2009-016970-33, 2009
- Acronym
- Extension
- Status last verified
- May 2021
- First submitted
- 30 Nov 2010
- Last updated
- 12 May 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Extension Protocol for Participants of Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle Including the Trochlea
- ClinicalTrials.gov ID
- NCT01251588
- Acronym / sponsor ID
- Extension / MACI00809
- Conditions
- Articular Cartilage Defects
- Keywords
- Cartilage legions, Symptomatic focal cartilage defects, Microfracture, MACI, Autologous chondrocyte
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 128 participants (actual)
- Lead sponsor
- Vericel CorporationIndustry (pharma, biotech, devices)
- Study start
- Dec 2010
- Primary completion
- Mar 2015 (actual)
- Study completion
- Mar 2015 (actual)
- First posted
- 2 Dec 2010 (estimated)
- Results
- Posted 27 Apr 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To examine the 5-year efficacy and safety of MACI implant, compared with arthroscopic microfracture, in participants who received study treatment in the SUMMIT study for treatment of symptomatic articular cartilage defects of the knee.
Detailed description
This study was an open-label, multicenter extension to the SUMMIT study designed to examine the 5-year efficacy and safety of MACI compared to arthroscopic microfracture in the treatment of articular cartilage defects of the knee in participants who received study treatment in the SUMMIT study. Follow-up to 2 years post-study treatment was completed as part of the SUMMIT study. Follow-up from 3 to 5 years post-study treatment in SUMMIT was completed in this extension study.
All 144 participants who received study treatment in the SUMMIT study were eligible for enrollment into this extension study. Participants had until the end of the visit window for the last visit of this extension study (ie, Week 260 + 6 weeks) to consent to enter this extension study.
Efficacy and safety assessments were performed at scheduled visits 3, 4, and 5 years following treatment in SUMMIT (ie, at Weeks 156, 208, and 260 postarthrotomy for patients treated with MACI implant or at Weeks 156, 208, and 260 postarthroscopy for patients treated with microfracture).
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MACI | – | Biological: autologous cultured chondrocytes on porcine collagen membraneautologous cultured chondrocytes on porcine collagen membrane implant received in previous MACI00206 study |
| Microfracture | – | Procedure: MicrofractureMicrofracture treatment received in previous MACI00206 study |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Randomized and received study treatment (MACI or microfracture) in the SUMMIT study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| autologous cultured chondrocytes on porcine collagen membraneAlso: MACI, matrix applied characterized autologous cultured chondrocytesImplantation received in the previous MACI00206 study | Biological | MACI |
| MicrofractureArthroscopic Microfracture treatment received in the previous MACI00206 study | Procedure or surgery | Microfracture |
Primary outcome
Change From MACI00206 Baseline for the Participant's Knee Injury and Osteoarthritis Outcome (KOOS) Pain and Function (Sports and Recreational Activities) Scores.
Time frame: MACI00206 Baseline to Week 156
The KOOS is a validated knee-specific instrument developed to assess the patients' opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). A 5-point Likert scale was used to record the response to each item ranging from 0 (no problems) to 4 (extreme problems). Within each subscale, items were added up and normalized to a value between 0 (extreme problems) and 100 (no problems). Subscales are not combined to calculate a total score.
13 secondary outcomes
Change From MACI00206 Baseline for the Participant's KOOS Pain and Function (Sports and Recreational Activities) Scores
Time frame: MACI00206 Baseline and Week 260
Magnetic Resonance Imaging (MRI) Assessments of Degree of Defect Fill
Time frame: Week 260
Proportion of Patients Who Achieve at Least a 10-point Improvement From MACI00206 Baseline in KOOS Pain and Function (Sports and Recreational Activities) Scores
Time frame: Up to week 260
The Proportion of Patients in Each Treatment Group Assessed as Treatment Failures
Time frame: Years 2 through 5 post treatment (MACI or microfracture)
Average Time to Treatment Failure
Time frame: Up to 260 weeks
Change From MACI00206 Baseline in the Remaining 3 Subscales (Activities of Daily Living, Quality of Life, and Other Symptoms) of KOOS
Time frame: MACI00206 Baseline and Week 260
Change From MACI00206 Baseline in the Patient's Evaluation of Overall Knee Condition Using the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form
Time frame: MACI00206 Baseline and Week 260
Change From MACI00206 Baseline in the Patient's Evaluation of Overall Knee Condition Using the Modified Cincinnati Knee Rating System
Time frame: MACI00206 Baseline and Week 260
Change From MACI00206 Baseline in the 12-Item Short-Form Health Survey (SF-12) Physical and Mental Component Scores
Time frame: MACI00206 Baseline and Week 260
Change From MACI00206 Baseline in the European Quality of Life 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) Score
Time frame: MACI00206 Baseline and Week 260
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs)
Time frame: Years 2 through 5 post treatment (MACI or microfracture)
Number of Participants Reporting Serious Adverse Events (SAEs)
Time frame: Years 2 through 5 post treatment (MACI or microfracture)
Number of Participants Having Subsequent Surgical Procedures (SSPs) in Target Knee
Time frame: Years 2 through 5 post treatment (MACI or microfracture)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Articular Cartilage Defects
Recruiting
BioPoly® Partial Resurfacing Knee Implant IDE
Knee Pain Chronic, Knee Osteoarthritis
RecruitingPhase 3
Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis
Knee Cartilage Defects
RecruitingPhase 3
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
Chondral Defect, Articular Cartilage Defect
RecruitingPhase 3
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Chondral Defect, Osteochondritis Dissecans (OCD)
Recruiting
Subchondral Drilling Diameter During CARTISTEM Implantation for Knee Cartilage Defects
Osteoarthritis, Knee, Articular Cartilage Defects of the Knee
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Monitor study director
Genzyme, a Sanofi Company
14 sites in 7 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Articular Cartilage Defects, run by Vericel Corporation at 14 sites in 7 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 14 sites in France, Netherlands, Poland, Czechia, Norway and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 27 Apr 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From MACI00206 Baseline for the Participant's Knee Injury and Osteoarthritis Outcome (KOOS) Pain and Function (Sports and Recreational Activities) Scores. (time frame: MACI00206 Baseline to Week 156). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2021.